Masaru Matsuda - May 27, 2024 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Signature
/s/ David Topper, as Attorney-in-Fact for Masaru Matsuda
Stock symbol
ARQT
Transactions as of
May 27, 2024
Transactions value $
-$15,988
Form type
4
Date filed
5/29/2024, 07:38 PM
Previous filing
May 3, 2024
Next filing
Dec 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Award $0 +4.88K +2.63% $0.00 190K May 27, 2024 Direct F1
transaction ARQT Common Stock Sale -$16K -1.78K -0.93% $9.01 189K May 28, 2024 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents performance stock units ("PSUs") initially granted on January 3, 2022 that were subject to a performance-based vesting condition. The vesting condition was determined to be satisfied on May 27, 2022. The PSUs will vest fully on May 27, 2025, subject to the Reporting Person's continued service to the Issuer on such vesting date.
F2 The sale was made pursuant to the Issuer's mandatory sell-to-cover requirements implemented to satisfy the tax withholding obligations associated with the vesting of the reporting person's PSUs.
F3 The transaction was executed in multiple trades in prices ranging from $8.99 to $9.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

Reporting Person's title: SVP General Counsel and Corporate Secretary